{"organizations": [], "uuid": "9fd3aa2718dd85f4dfedd461ca77228e6b0212cf", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-ligand-enters-into-agreement-with/brief-ligand-enters-into-agreement-with-venbio-idUSFWN1RC02W", "country": "US", "domain_rank": 408, "title": "BRIEF-Ligand Enters Into Agreement With venBio", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-30T16:28:00.000+03:00", "replies_count": 0, "uuid": "9fd3aa2718dd85f4dfedd461ca77228e6b0212cf"}, "author": "", "url": "https://www.reuters.com/article/brief-ligand-enters-into-agreement-with/brief-ligand-enters-into-agreement-with-venbio-idUSFWN1RC02W", "ord_in_thread": 0, "title": "BRIEF-Ligand Enters Into Agreement With venBio", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "ligand pharmaceuticals inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "ligand", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 30, 2018 / 1:28 PM / Updated 11 minutes ago BRIEF-Ligand Enters Into Agreement With venBio Reuters Staff 1 Min Read \nMarch 30 (Reuters) - Ligand Pharmaceuticals Inc: \n* LIGAND ENTERS INTO AGREEMENT WITH VENBIO TO MAKE WORLDWIDE OMNIABÂ® PLATFORM LICENSE ACCESSIBLE TO PORTFOLIO COMPANIES Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-30T16:28:00.000+03:00", "crawled": "2018-03-30T16:43:34.004+03:00", "highlightTitle": ""}